Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07139743

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis (BOBCAT)

A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis

Sponsor: Autolus Limited

Conditions Progressive Multiple Sclerosis

Interventions Obecabtagene autoleucel (obe-cel)

Updated 4 times since 2025 Last updated: Feb 26, 2026 Started: Aug 4, 2025 Primary completion: Aug 15, 2029 Completion: Aug 15, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Progressive Multiple Sclerosis, this trial is actively recruiting participants. The trial is conducted by Autolus Limited and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE1
Oct 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1

First recorded

Aug 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Autolus Limited

Data source: Autolus Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom